Anne Cooper - Concepedia

Author

Anne Cooper

AstraZeneca (United Kingdom)

Also Known As

A Cooper, A E Cooper, A. Cooper, A.E. Cooper, Anne Cooper, Anne E. Cooper

Publications

986

Citations

H-Index

Concepts

All Affiliations

AstraZeneca (United Kingdom)Loughborough University AstraZeneca (Sweden)University of California, Davis Emory University

About

Anne Cooper is an author at AstraZeneca (United Kingdom) specializing in medicine, drug discovery, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	333
2	Natural Sciences	4	4	161
3	Biochemistry	3	3	170
4	Social Sciences	1	1	72
5	Chemical Biology	1	1	26

Anne Cooper

Publications

804

Citations

H-Index

Page 1

	Year	Citations
Detection of Autoantibodies to Recombinant Mitochondrial Proteins in Patients with Primary Biliary Cirrhosis Judy Van de Water, Anne Cooper, Charles D. Surh, New England Journal of Medicine	1989	203
Differential Multidrug Resistance-Associated Protein 1 through 6 Isoform Expression and Function in Human Intestinal Epithelial Caco-2 Cells Hannah M. Prime-Chapman, Richard A. Fearn, Anne Cooper, Journal of Pharmacology and Experimental Therapeutics	2004	141
Hit-to-lead studies: the discovery of potent, orally active, thiophenecarboxamide IKK-2 inhibitors Andrew Baxter, Steve Brough, Anne Cooper, Bioorganic & Medicinal Chemistry Letters Medicinal ChemistryThiophenecarboxamide Ikk-2 InhibitorsHit IdentificationDrug TargetBiochemistry	2004	90
A longitudinal pilot proton MRS investigation of the manic and euthymic states of bipolar disorder Roscoe O. Brady, Anne Cooper, John Eric Jensen, Translational Psychiatry NeuropsychologyNeurophysiological BiomarkersNeuropsychiatrySocial SciencesMood Symptom	2012	72
The predominance of IgG3 and IgM isotype antimitochondrial autoantibodies against recombinant fused mitochondrial polypeptide in patients with primary biliary cirrhosis Charles D. Surh, Anne Cooper, Ross L. Coppel, Hepatology	1988	69
Hit-to-Lead studies: The discovery of potent, orally bioavailable thiazolopyrimidine CXCR2 receptor antagonists Andrew Baxter, Anne Cooper, Elizabeth Kinchin, Bioorganic & Medicinal Chemistry Letters Drug TargetBiochemistryMedicineRational Drug DesignPharmacological Agent	2005	54
Hit-to-Lead studies: The discovery of potent, orally bioavailable triazolethiol CXCR2 receptor antagonists Andrew Baxter, Colin Bennion, Janice Bent, Bioorganic & Medicinal Chemistry Letters Pharmaceutical ScienceDrug TargetPharmacologyLead IdentificationHit-to-lead Studies	2003	46
The discovery of novel, potent and highly selective inhibitors of inducible nitric oxide synthase (iNOS) David R. Cheshire, Anders Åberg, Gunilla Andersson, Bioorganic & Medicinal Chemistry Letters Medicinal ChemistryBiochemistryReactive Nitrogen SpecieNatural SciencesMedicine	2011	26
Modulators of the human CCR5 receptor. Part 2: SAR of substituted 1-(3,3-diphenylpropyl)-piperidinyl phenylacetamides John G. Cumming, Anne Cooper, Ken Grime, Bioorganic & Medicinal Chemistry Letters Medicinal ChemistryG Protein-coupled ReceptorMedicineNatural SciencesHuman Ccr5 Receptor	2005	26
Prediction of Efficacious Inhalation Lung Doses via the Use of In Silico Lung Retention Quantitative Structure-Activity Relationship Models and In Vitro Potency Screens Anne Cooper, Tim Potter, Tim Luker Drug Metabolism and Disposition	2010	24

Page 1